- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT02402660
Fase 2 Tolerabilitet og virkninger af ALK-001 på Stargardts sygdom (TEASE)
En fase 2 multicenter, dobbeltmasket, randomiseret, placebokontrolleret undersøgelse for at undersøge langsigtet sikkerhed, tolerabilitet, farmakokinetik og virkninger af ALK-001 på udviklingen af Stargardts sygdom
The purpose of this study is to determine the long term safety and tolerability of ALK-001 (C20-D3-retinyl acetate), and to explore the effects of ALK-001 on the progression of Stargardt disease in patients between the ages of 8 and 70 years old.
Funding Source - FDA OOPD
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
This study evaluates the effects of orally-administered ALK-001 on the progression of Stargardt disease (ABCA4-related). Stargardt disease is a rare genetic disorder that leads to damage to the retina and results in legal blindness. Stargardt disease is caused by a defective ABCA4 gene, which affects the processing of vitamin A in the eye and leads to the formation of toxic vitamin A aggregates (called "vitamin A dimers") in the eye. Vitamin A dimers are thought to contribute to vision loss in Stargardt disease. ALK-001, the investigational drug, is a chemically-modified vitamin A designed as a replacement of vitamin A to prevent the formation of toxic vitamin A dimers in the eye. Trial participants will receive either ALK-001 or placebo, and follow-up visits will take place periodically for up to 24 months. There is currently no treatment for Stargardt disease.
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
Arizona
-
Phoenix, Arizona, Forenede Stater, 85020
- Alkeus Site
-
-
California
-
Los Angeles, California, Forenede Stater, 90095
- Alkeus Site
-
-
Colorado
-
Aurora, Colorado, Forenede Stater, 80045
- Alkeus Site
-
-
Florida
-
Gainesville, Florida, Forenede Stater, 32601
- Alkeus Site
-
Miami, Florida, Forenede Stater, 33136
- Alkeus Site
-
-
Indiana
-
Indianapolis, Indiana, Forenede Stater, 46202
- Alkeus Site
-
-
Maryland
-
Baltimore, Maryland, Forenede Stater, 21287
- Alkeus Site
-
-
Michigan
-
Grand Rapids, Michigan, Forenede Stater, 49546
- Alkeus Site
-
-
New York
-
New York, New York, Forenede Stater, 10032
- Alkeus Site
-
Westbury, New York, Forenede Stater, 11590
- Alkeus Site
-
-
Texas
-
Houston, Texas, Forenede Stater, 77025
- Alkeus Site
-
-
Utah
-
Salt Lake City, Utah, Forenede Stater, 84132
- Alkeus Site
-
-
Washington
-
Silverdale, Washington, Forenede Stater, 98383
- Alkeus Site
-
-
Wisconsin
-
Milwaukee, Wisconsin, Forenede Stater, 53226
- Alkeus Site
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Simplified Inclusion Criteria:
- Male or female between 8 and 70 years old (inclusive), with any visual acuity
- Has a clinical diagnosis of typical autosomal recessive Stargardt macular dystrophy (STGD1)
- Has provided a genetic report indicating at least two ABCA4 disease-causing mutations. When only one ABCA4 disease-causing mutation is reported, sponsor's permission will be required.
- At least one eye (called the "primary study eye") must have at least one well-demarcated area of significantly reduced autofluorescence as imaged by fundus autofluorescence (FAF), have decreased retinal sensitivity as measured by microperimetry, or have maculopathy expected to progress over the duration of the study
- Primary study eye must have clear ocular media and adequate pupillary dilation, including no allergy to dilating eyedrops, to permit good quality retinal imaging
- Healthy as judged by investigator
- Able and willing to comply with study requirements, restrictions and instructions and is likely to complete the 24-month study
- Has signed and dated the informed consent forms (or assent where appropriate) to participate
- Female of childbearing potential has signed the informed consent about birth defects or attestation on contraception requirements
Main Exclusion Criteria:
- Has taken disallowed items (supplement containing vitamin A or beta-carotene, liver-based products, or prescription oral retinoid medications) over the past 30 days
- Is lactating, pregnant, or has a positive serum or urine pregnancy test at screening or at randomization
- Has concurrent medical condition or history, which in the opinion of the investigator, is likely to prevent compliance with the protocol and/or interfere with absorption of ALK-001 or study procedures
- Has clinically significant abnormal laboratory result(s) at screening
- Has active or historical acute or chronic liver disorder
- Has active or historical ocular disorder in the primary study eye that, in the opinion of the investigator, may confound assessment of the retina morphologically or functionally (this could include for example cataract surgery within the past 6 months, choroidal neovascularization (CNV), glaucoma, recurring uveitis, diabetic retinopathy, other retinal disease, etc.)
- Has had intraocular surgery or injections in the primary study eye within 90 days of the screening visit
- Has a clinically significant abnormal electrocardiogram (ECG), or has a corrected QT interval (QTc) that is 450 ms or greater
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Firedobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: ALK-001
Daily, oral administration of one capsule. See details below. |
Daily, oral administration for 24 months
Andre navne:
|
|
Placebo komparator: Placebo
Daily, oral administration of one capsule. See details below. |
Daily, oral administration for 24 months |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Sikkerhed og tolerabilitet på 24 måneders daglig dosering af ALK-001 vurderet ved forekomst og/eller klinisk signifikante ændringer af en kombination af okulære og ikke-okulære bivirkninger
Tidsramme: Fra baseline til 24 måneder
|
Fra baseline til 24 måneder
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Farmakokinetisk profil af ALK-001 afledt af koncentrationerne af ALK-001 og metabolitter i plasma
Tidsramme: Op til 24 måneder
|
Op til 24 måneder
|
|
|
Effects of ALK-001 on the progression of Stargardt disease
Tidsramme: From baseline to 24 months
|
Combination of changes in atrophic lesion size, best corrected visual acuity (BCVA), and ocular assessments. |
From baseline to 24 months
|
Samarbejdspartnere og efterforskere
Sponsor
Publikationer og nyttige links
Generelle publikationer
- Ma L, Kaufman Y, Zhang J, Washington I. C20-D3-vitamin A slows lipofuscin accumulation and electrophysiological retinal degeneration in a mouse model of Stargardt disease. J Biol Chem. 2011 Mar 11;286(10):7966-7974. doi: 10.1074/jbc.M110.178657. Epub 2010 Dec 14.
- Kaufman Y, Ma L, Washington I. Deuterium enrichment of vitamin A at the C20 position slows the formation of detrimental vitamin A dimers in wild-type rodents. J Biol Chem. 2011 Mar 11;286(10):7958-7965. doi: 10.1074/jbc.M110.178640. Epub 2010 Nov 12.
- Mihai DM, Jiang H, Blaner WS, Romanov A, Washington I. The retina rapidly incorporates ingested C20-D(3)-vitamin A in a swine model. Mol Vis. 2013 Jul 25;19:1677-83. Print 2013.
- Charbel Issa P, Barnard AR, Herrmann P, Washington I, MacLaren RE. Rescue of the Stargardt phenotype in Abca4 knockout mice through inhibition of vitamin A dimerization. Proc Natl Acad Sci U S A. 2015 Jul 7;112(27):8415-20. doi: 10.1073/pnas.1506960112. Epub 2015 Jun 23.
- Saad L, Washington I. Can Vitamin A be Improved to Prevent Blindness due to Age-Related Macular Degeneration, Stargardt Disease and Other Retinal Dystrophies? Adv Exp Med Biol. 2016;854:355-61. doi: 10.1007/978-3-319-17121-0_47.
- Zhang D, Robinson K, Washington I. C20D3-Vitamin A Prevents Retinal Pigment Epithelium Atrophic Changes in a Mouse Model. Transl Vis Sci Technol. 2021 Dec 1;10(14):8. doi: 10.1167/tvst.10.14.8.
- Zhang D, Robinson K, Saad L, Washington I. Vitamin A cycle byproducts impede dark adaptation. J Biol Chem. 2021 Sep;297(3):101074. doi: 10.1016/j.jbc.2021.101074. Epub 2021 Aug 12.
- Kay CN, Saad L, DeBartolomeo G, Bressler N, Tsang SH, Stepien K, Bernstein P, Lam BL, Washington I, Gorin MB; TEASE-1 Study Group. Safety and Effects of Gildeuretinol Acetate on Retinal Atrophic Lesions in Stargardt Disease: The TEASE-1 Randomized Clinical Trial. JAMA Ophthalmol. 2026 Sep 3:e263662. doi: 10.1001/jamaophthalmol.2026.3662. Online ahead of print.
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Anslået)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- ALK001-P1002
- R01FD004098 (U.S. FDA-tilskud/-kontrakt)
- R01FD006016 (Andet bevillings-/finansieringsnummer: FDA OOPD)
- R01FD006316 (U.S. FDA-tilskud/-kontrakt)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .